Nektar TherapeuticsFind Ratings Reports
NEKTAR THERAPEUTICS's gross profit margin for the second quarter of its fiscal year 2021 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its subsector. NEKTAR THERAPEUTICS is extremely liquid. Currently, the Quick Ratio is 7.85 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has decreased from the same period last year.
At the same time, stockholders' equity ("net worth") has significantly decreased by 27.96% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY21||Q2 FY20|
|Net Sales ($mil)||28.33||48.85|
|Net Income ($mil)||-125.52||-80.0|
|Balance Sheet||Q2 FY21||Q2 FY20|
|Cash & Equiv. ($mil)||1000.07||1038.4|
|Total Assets ($mil)||1371.35||1594.88|
|Total Debt ($mil)||336.51||225.06|
|Profitability||Q2 FY21||Q2 FY20|
|Gross Profit Margin||-376.48||-152.56|
|Return on Assets||-34.58||-26.92|
|Return on Equity||-52.41||-34.18|
|Debt||Q2 FY21||Q2 FY20|
|Share Data||Q2 FY21||Q2 FY20|
|Shares outstanding (mil)||183.77||178.81|
|Div / share||0.0||0.0|
|Book value / share||4.92||7.03|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||846081.0||881634.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 3.35 indicates a discount versus the S&P 500 average of 4.61 and a significant discount versus the subsector average of 9.36. The price-to-sales ratio is well above both the S&P 500 average and the subsector average, indicating a premium. The valuation analysis reveals that, NEKTAR THERAPEUTICS seems to be trading at a premium to investment alternatives.
|NKTR NM||Peers 29.20||NKTR NM||Peers 19.00|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
NKTR's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
NKTR's P/CF is negative making the measure meaningless.
|NKTR NM||Peers 15.83||NKTR NA||Peers 0.53|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
NKTR's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|NKTR 3.35||Peers 9.36||NKTR -8.23||Peers -89.23|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
NKTR is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
NKTR is expected to have an earnings growth rate that significantly exceeds its peers.
|NKTR 28.77||Peers 10.12||NKTR -35.10||Peers 26.17|
Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
NKTR is trading at a significant premium to its subsector.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
NKTR significantly trails its peers on the basis of sales growth.